KR20240121820A - 이형이량체 릴랙신 융합체를 이용한 치료 - Google Patents

이형이량체 릴랙신 융합체를 이용한 치료 Download PDF

Info

Publication number
KR20240121820A
KR20240121820A KR1020247023033A KR20247023033A KR20240121820A KR 20240121820 A KR20240121820 A KR 20240121820A KR 1020247023033 A KR1020247023033 A KR 1020247023033A KR 20247023033 A KR20247023033 A KR 20247023033A KR 20240121820 A KR20240121820 A KR 20240121820A
Authority
KR
South Korea
Prior art keywords
relaxin
chain
fusion
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023033A
Other languages
English (en)
Korean (ko)
Inventor
리처드 토마스 조지 주니어
캐슬린 마리 코놀리
사미 알리 압델 하페스 오마르
앤더스 가브리엘슨
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20240121820A publication Critical patent/KR20240121820A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020247023033A 2021-12-15 2022-12-14 이형이량체 릴랙신 융합체를 이용한 치료 Pending KR20240121820A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163289687P 2021-12-15 2021-12-15
US63/289,687 2021-12-15
US202263386812P 2022-12-09 2022-12-09
US63/386,812 2022-12-09
PCT/EP2022/086001 WO2023111112A1 (en) 2021-12-15 2022-12-14 Treatment using heterodimeric relaxin fusions

Publications (1)

Publication Number Publication Date
KR20240121820A true KR20240121820A (ko) 2024-08-09

Family

ID=84888900

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023033A Pending KR20240121820A (ko) 2021-12-15 2022-12-14 이형이량체 릴랙신 융합체를 이용한 치료

Country Status (8)

Country Link
US (1) US20250295737A1 (https=)
EP (1) EP4447998A1 (https=)
JP (1) JP2024546877A (https=)
KR (1) KR20240121820A (https=)
AU (1) AU2022410335A1 (https=)
CA (1) CA3241355A1 (https=)
IL (1) IL313386A (https=)
WO (1) WO2023111112A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN120813595A (zh) 2023-03-03 2025-10-17 阿斯利康(瑞典)有限公司 包含异源二聚体松弛素融合蛋白的药物制剂及其用途
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
EP3574004A1 (en) 2017-01-25 2019-12-04 Medimmune, LLC Relaxin fusion polypeptides and uses thereof
CN115768801A (zh) * 2020-05-08 2023-03-07 哈佛学院院长等 工程化松弛素及其使用方法

Also Published As

Publication number Publication date
IL313386A (en) 2024-08-01
US20250295737A1 (en) 2025-09-25
AU2022410335A1 (en) 2024-07-18
JP2024546877A (ja) 2024-12-26
CA3241355A1 (en) 2023-06-22
EP4447998A1 (en) 2024-10-23
WO2023111112A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
TWI899263B (zh) 異源二聚體鬆弛素融合物及其用途
US11845782B2 (en) Relaxin fusion polypeptides and uses thereof
US20250295737A1 (en) Treatment Using Heterodimeric Relaxin Fusions
JP2013531488A (ja) エキセンジン−４の融合タンパク質およびその類似体、これらの調製方法および使用
US20250333467A1 (en) Relaxin-2 fusion protein analogs and methods of using same
TW202426037A (zh) 使用異二聚鬆弛素融合物之治療方法
TW202438534A (zh) 使用異二聚物鬆弛素融合體的給藥方案
EA052557B1 (ru) Лечение с применением гетеродимерных слитых продуктов на основе релаксина
CN118434437A (zh) 使用异源二聚体松弛素融合物进行的治疗
EA049488B1 (ru) Гетеродимерные слитые продукты на основе релаксина и пути их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000